Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials

Oncology

Volumn 81, Issue 3-4, 2011, Pages 143-150

  Yang, Shih Hung ^a   Kuo, Yu Hsuan ^a   Tien, Yu Wen ^a   Hsu, Chiun ^a,b   Hsu, Chih Hung ^a,b   Kuo, Sung Hsin ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Clinical trials; Gemcitabine based chemotherapy; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN; PEMETREXED; TEGAFUR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROGNOSIS; REPUBLIC OF KOREA; TREATMENT OUTCOME;

EID: 80054797356     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000330817     Document Type: Article

References (23)

1. Fatima J, Schnelldorfer T, Barton J, et al: Pancreatoduodenectomy for ductal adenocarcinoma: Implications of positive margin on survival. Arch Surg 2010; 145: 167-172.
2. Garcea G, Dennison AR, Ong SL, et al: Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007; 33: 892-897.
3. Riediger H, Keck T, Wellner U, et al: The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13: 1337-1344.
4. Morganti AG, Massaccesi M, La Torre G, et al: A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol 2010; 17: 194-205.
5. Ishii H, Furuse J, Boku N, et al, JCOG Gastrointestinal Oncology Study Group: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010; 40: 573-579.
6. Merl MY, Abdelghany O, Li J, Saif MW: Firstline treatment of metastatic pancreatic adenocarcinoma: Can we do better? Highlights from the '2010 ASCO Annual Meeting', Chicago, Ill., USA. JOP 2010; 11: 317-320.
7. Moore MJ, Goldstein D, Hamm J, et al Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
8. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-3610.
9. Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-3622.
10. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
11. Bayraktar S, Bayraktar UD, Rocha-Lima CM: Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol 2010; 16: 673-682.
12. Kalser MH, Barkin J, MacIntyre JM: Pancreatic cancer: Assessment of prognosis by clinical presentation. Cancer 1985; 56: 397-402.
13. Chu CK, Sarmiento JM, Park J, et al: Differences in presentation and perioperative outcome after pancreaticoduodenectomy for cancer and benign pancreatitis. Am Surg 2010; 76: 606-613.
14. Boeck S, Hinke A, Wilkowski R, Heinemann V: Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13: 224-227.
15. Sultana A, Smith CT, Cunningham D, et al: Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25: 2607-2615.
16. Oztop I, Yilmaz U, Yavuzsen T, et al: Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy 2004; 50: 127-132.
17. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23: 3509-3516.
18. Ch'ang HJ, Huang CL, Wang HP, et al: Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-hour infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 64: 1173-1179.
19. Reni M, Cordio S, Milandri C, et al: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6: 369-376.
20. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. N Engl J Med 2011; 364: 1817-1825.
21. Venook AP, Egorin MJ, Rosner GL, et al: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18: 2780-2787.
22. Wynder EL: An epidemiological evaluation of the causes of cancer of the pancreas. Cancer Res 1975; 35: 2228-2233.
23. Koeppler H, Duru M, Grundheber M, et al: Palliative treatment of advanced pancreatic carcinoma in community-based oncology group practices. J Support Oncol 2004; 2: 159-163.